IP Library Granted Patent US 8,790,901
Granted Patent B2
US 8,790,901 · App. 13/326,211 · Granted Jul 29, 2014

Microorganisms and methods for producing unsaturated fatty acids

Inventors: Subhayu Basu (Chestnut Hill, MA); Gaozhong Shen (Brighton, MA); Brett Boghigian (Boston, MA); David Young (Cambridge, MA); David Berry (Cambridge, MA); Geoffrey von Maltzahn (Cambridge, MA)
Assignee: Pronutria, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,790,901
App. No.
13/326,211
Granted
Jul 29, 2014
Kind
B2
Abstract

Methods of producing an unsaturated free fatty acid comprising at least 18 carbon atoms are provided. In some embodiments, the methods comprise culturing an engineered microorganism in a culture medium, wherein the engineered microorganism comprises at least one recombinant enzyme selected from acyl-lipid desaturase delta-9 (EC:1.14.19.1), acyl-lipid desaturase delta-12 (EC:1.14.19.6), acyl-lipid desaturase delta-15 (EC:1.14.19.-), and thioesterase (EC:3.1.2.14). Engineered microorganisms comprising at least one of those recombinant enzymes are also provided. The methods and organisms can be used to produce at least one free fatty acid selected from oleic acid, linoleic acid and α-linolenic acid.

Claims (36)

1. A method for producing an unsaturated free fatty acid comprising at least 18 carbon atoms, the method comprising:

culturing an engineered microorganism in a culture medium, wherein the engineered microorganism comprises at least one recombinant acyl-lipid desaturase specific for a substrate comprising at least 18 carbon atoms, and wherein production of acyl-ACP synthetase (EC:6.2.1.20) is reduced or eliminated in the engineered microorganism, and

wherein the amount of the unsaturated free fatty acid comprising at least 18 carbon atoms produced by the engineered microorganism is increased relative to the amount of the unsaturated free fatty acid comprising at least 18 carbon atoms produced by an otherwise identical microorganism lacking the at least one recombinant acyl-lipid desaturase.

2. The method of claim 1 , wherein the at least one recombinant acyl-lipid desaturase is selected from acyl-lipid desaturase delta-9 (EC:1.14.19.1), acyl-lipid desaturase delta-12 (EC:1.14.19.6), and acyl-lipid desaturase delta-15 (EC:1.14.19.-).

3. The method of claim 2 , wherein the unsaturated free fatty acid

comprising at least 18 carbon atoms is selected from oleic acid, linoleic acid and α-linolenic acid.

4. The method of claim 1 , wherein the at least one recombinant acyl-lipid desaturase is a recombinant acyl-lipid desaturase delta-9 (EC:1.14.19.1), and

wherein the engineered microorganism produces oleic acid, and the production of oleic acid is increased in the engineered microorganism relative to production of oleic acid by an otherwise identical microorganism lacking the recombinant acyl-lipid desaturase delta-9 (EC:1.14.19.1).

5. The method of claim 1 , wherein the engineered microorganism

comprises a recombinant acyl-lipid desaturase delta-12 (EC:1.14.19.6), and

wherein the engineered microorganism produces linoleic acid, and the production of linoleic acid is increased in the engineered microorganism relative to production of linoleic acid by an otherwise identical microorganism lacking the recombinant acyl-lipid desaturase delta-12 (EC:1.14.19.6).

6. The method of claim 1 , wherein the engineered microorganism

comprises a recombinant acyl-lipid desaturase delta-15 (EC:1.14.19.-), and

wherein the engineered microorganism produces α-linolenic acid, and the production of α-linolenic acid is increased in the engineered microorganism relative to production of α-linolenic acid by an otherwise identical microorganism lacking the recombinant acyl-lipid desaturase delta-15 (EC:1.14.19.-).

7. The method of claim 1 , wherein the engineered microorganism

comprises a recombinant acyl-lipid desaturase delta-12 (EC:1.14.19.6) and a recombinant acyllipid

desaturase delta-15 (EC:1.14.19.-),

wherein the engineered microorganism produces α-linolenic acid, and the production of α-linolenic acid is increased in the engineered microorganism relative to production of α-linolenic acid by an otherwise identical microorganism lacking at least one of the recombinant acyl-lipid desaturase delta-12 (EC:1.14.19.6) and the recombinant acyl-lipid desaturase delta-15 (EC:1.14.19.-).

8. The method of claim 7 , wherein the engineered microorganism further

comprises a recombinant acyl-lipid desaturase delta-9 (EC:1.14.19.1),

wherein the production of α-linolenic acid is increased in the engineered microorganism relative to production of α-linolenic acid by an otherwise identical microorganism lacking at least one of the recombinant acyl-lipid desaturase delta-9 (EC:1.14.19.1), the recombinant acyllipid desaturase delta-12 (EC:1.14.19.6) and the recombinant acyl-lipid desaturase delta-15 (EC:1.14.19.-).

9. The method of claim 1 , wherein the engineered microorganism

comprises a recombinant acyl-lipid desaturase delta-9 (EC:1.14.19.1), a recombinant acyl-lipid desaturase delta-12 (EC:1.14.19.6) and a recombinant acyl-lipid desaturase delta-15 (EC:1.14.19.-),

wherein the engineered microorganism produces oleic acid, linoleic acid and α-linolenic acid, and the production of at least one of oleic acid, linoleic acid and α-linolenic acid is increased in the engineered microorganism relative to the production of the corresponding oleic acid, linoleic acid and α-linolenic acid by an otherwise identical microorganism lacking at least one of the recombinant acyl-lipid desaturase delta-9 (EC:1.14.19.1), the recombinant acyl-lipid desaturase delta-12 (EC:1.14.19.6) and the recombinant acyl-lipid desaturase delta-15 (EC:1.14.19.-).

10. The method of claim 1 , wherein the engineered microorganism comprises recombinant subunits accB, accC, accD, and accA of the acetyl-CoA carboxylase enzyme (EC:6.4.1.2).

11. The method of claim 1 , wherein the engineered microorganism further comprises a recombinant thioesterase (EC:3.1.2.14).

12. The method of claim 11 , wherein the recombinant thioesterase (EC:3.1.2.14) is localized to the cytosol.

13. The method of claim 1 , wherein the engineered microorganism is a cyanobacterium.

14. The method of claim 1 , wherein the engineered microorganism is Escherichia coli.

15. An engineered microorganism comprising at least one recombinant nucleic acid encoding an acyl-lipid desaturase specific for a substrate comprising at least 18 carbon atoms, and wherein the engineered microorganism comprises at least one genetic modification that reduces or eliminates production of acyl-ACP synthetase (EC:6.2.1.20).

16. The engineered microorganism of claim 15 , wherein the engineered microorganism further comprises a recombinant nucleic acid encoding a thioesterase (EC:3.1.2.14).

17. The engineered microorganism of claim 15 , wherein the at least one acyl-lipid desaturase specific for a substrate comprising at least 18 carbon atoms is selected from acyl-lipid desaturase delta-9 (EC:1.14.19.1), acyl-lipid desaturase delta-12 (EC:1.14.19.6), and acyl-lipid desaturase delta-15 (EC:1.14.19.-).

18. The engineered microorganism of claim 15 , wherein the engineered microorganism further comprises one or more recombinant nucleic acid that together encode subunits accB, accC, accD, and accA of the acetyl-CoA carboxylase enzyme (EC:6.4.1.2).

19. The engineered microorganism of claim 16 , wherein the recombinant nucleic acid encoding a thioesterase (EC:3.1.2.14) encodes a recombinant thioesterase (EC:3.1.2.14) localized to the cytosol of the engineered microorganism.

20. The engineered microorganism of claim 15 , wherein the engineered microorganism is a cyanobacterium.

21. The engineered microorganism of claim 15 , wherein the engineered microorganism is Escherichia coli.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2023
From: AXCELLA HEALTH INC.
To: AXCELLA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 066125/0228 →
RELEASE OF SECURITY INTEREST Recorded Dec 15, 2022
From: SLR INVESTMENT CORP.
To: AXCELLA HEALTH INC.
Reel/Frame 062137/0569 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 2, 2021
From: AXCELLA HEALTH INC.
To: SLR INVESTMENT CORP., AS AGENT
Reel/Frame 057435/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2016
From: PRONUTRIA BIOSCIENCES, INC.
To: AXCELLA HEALTH INC.
Reel/Frame 040249/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2016
From: PRONUTRIA, INC.
To: PRONUTRIA BIOSCIENCES, INC.
Reel/Frame 038177/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2013
From: YOUNG, DAVID; BERRY, DAVID; VON MALTZAHN, GEOFFREY
To: PRONUTRIA, INC.
Reel/Frame 030992/0508 →
CHANGE OF NAME Recorded Oct 16, 2012
From: ESSENTIENT, INC.
To: PRONUTRIA, INC.
Reel/Frame 029140/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2011
From: BASU, SUBHAYU; SHEN, GAOZHONG; BOGHIGIAN, BRETT
To: ESSENTIENT, INC.
Reel/Frame 027393/0980 →
Continuity (1)
Related Publication 20120116108A1 · May 10, 2012